Ocrelizumab reduces progression of brain atrophy in patients with multiple sclerosis
Introduction: Multiple sclerosis (MS) is a clinical entity characterised by both inflammatory and neurodegenerative components. Ocrelizumab is an anti-CD20 monoclonal antibody that has demonstrated high clinical efficacy in controlling neuroinflammation, and evidence suggests it may also exert a ben...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Elsevier
2026-04-01
|
| Reeks: | Neurology Perspectives |
| Onderwerpen: | |
| Online toegang: | http://www.sciencedirect.com/science/article/pii/S2667049625000341 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|